EZB Stock Overview A life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Enzo Biochem, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Enzo Biochem Historical stock prices Current Share Price US$0.57 52 Week High US$1.31 52 Week Low US$0.57 Beta 0.80 1 Month Change -17.39% 3 Month Change -44.12% 1 Year Change -50.00% 3 Year Change -79.79% 5 Year Change -74.32% Change since IPO -99.13%
Recent News & Updates
Enzo Biochem Receives Non-Compliance Letter from NYSE Jan 16
Enzo Biochem Receives Non-Compliance Letter from NYSE Jan 15 Enzo Biochem, Inc., Annual General Meeting, Jan 15, 2025
New minor risk - Dividend sustainability Nov 01 Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024 Oct 30
High number of new and inexperienced directors Sep 20 See more updates
Enzo Biochem Receives Non-Compliance Letter from NYSE Jan 16
Enzo Biochem Receives Non-Compliance Letter from NYSE Jan 15 Enzo Biochem, Inc., Annual General Meeting, Jan 15, 2025
New minor risk - Dividend sustainability Nov 01 Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024 Oct 30
High number of new and inexperienced directors Sep 20
Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023) Jun 16
Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.23 loss in 2Q 2023) Mar 14 Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer
Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024 Dec 23
Enzo Biochem, Inc. announced delayed annual 10-K filing Nov 01
High number of new directors Nov 01
Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors Oct 31
High number of new and inexperienced directors Sep 10
Enzo Biochem, Inc. Announces CEO Changes Sep 07
Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027 May 10
Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022) Mar 21
First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022) Dec 14
Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022 Dec 08
CEO & Director recently bought €190k worth of stock Nov 29
Insider recently bought €4.8m worth of stock Nov 25
High number of new and inexperienced directors Nov 16
Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023 Nov 09 Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022
Full year 2022 earnings released: US$0.38 loss per share (vs US$0.16 profit in FY 2021) Oct 16
Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022 Oct 11
Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2 Sep 27
Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week Aug 12
Enzo Biochem, Inc. Announces Executive Changes Aug 04
Independent Director recently bought €258k worth of stock Jul 08
Independent Director recently bought €262k worth of stock Jun 18
Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021) Jun 11
Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022 Jun 03
High number of new and inexperienced directors Apr 27
Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test Apr 20
Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022 Apr 04
Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022 Apr 02
Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions Mar 29
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Mar 16 Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022 Mar 10
High number of new and inexperienced directors Feb 02
Less than half of directors are independent Jan 07
Insider recently bought €2.2m worth of stock Dec 29
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Dec 16
Insider recently bought €1.3m worth of stock Oct 24
Investor sentiment deteriorated over the past week Oct 21
Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020) Oct 13
Insider recently bought €2.1m worth of stock Oct 07 Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index
Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020) Jun 12
Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director Mar 21
Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020) Mar 17
Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO Mar 16
Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants Mar 04
Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021 Mar 02
New 90-day high: €2.76 Feb 06
Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin Feb 04
Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees Jan 22
Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2 Jan 05
New 90-day high: €2.30 Jan 05
New 90-day high: €2.10 Dec 15
First quarter 2021 earnings released: EPS US$0.006 Dec 11
Enzo Biochem, Inc. to Report Q1, 2021 Results on Dec 09, 2020 Dec 03
Enzo Biochem, Inc. Announces Appointment of Ian B. Walters to Board of Directors Nov 26
Enzo Biochem, Inc. Appoints Mary Tagliaferri to Its Board of Directors Nov 19
Enzo Biochem, Inc. Announces Resignation of Peter J. Clemens, IV from the Board of Directors as Class II Director Nov 18
Enzo Biochem, Inc. Launches Portable Microplate Reader for Use with its Elisa and Assay Kits to Simplify Laboratory Workflow Nov 06
Enzo Biochem Launches GoTestMeNow Online Platform for Consumers to Directly Order COVID-19 Laboratory Tests Oct 29
New 90-day low: €1.66 Oct 23
Full year earnings released - €0.60 loss per share Oct 15
Enzo Biochem, Inc. to Report Q4, 2020 Results on Oct 13, 2020 Oct 07
New 90-day low - €1.79 Sep 01 Shareholder Returns EZB DE Healthcare DE Market 7D -8.1% 1.5% 1.9% 1Y -50.0% 39.2% 15.1%
See full shareholder returns
Return vs Market: EZB underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is EZB's price volatile compared to industry and market? EZB volatility EZB Average Weekly Movement 11.2% Healthcare Industry Average Movement 4.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: EZB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EZB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
Show more Enzo Biochem, Inc. Fundamentals Summary How do Enzo Biochem's earnings and revenue compare to its market cap? EZB fundamental statistics Market cap €30.54m Earnings (TTM ) -€6.96m Revenue (TTM ) €29.24m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EZB income statement (TTM ) Revenue US$30.31m Cost of Revenue US$16.86m Gross Profit US$13.46m Other Expenses US$20.67m Earnings -US$7.21m
Last Reported Earnings
Oct 31, 2024
Earnings per share (EPS) -0.14 Gross Margin 44.39% Net Profit Margin -23.79% Debt/Equity Ratio 0.5%
How did EZB perform over the long term?
See historical performance and comparison Dividends
16.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 09:17 End of Day Share Price 2025/01/31 00:00 Earnings 2024/10/31 Annual Earnings 2024/07/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Enzo Biochem, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bradley Berning Craig-Hallum Capital Group LLC Reni Benjamin Rodman & Renshaw, LLC Jack Wallace Sidoti & Company, LLC
Show 1 more analysts 
